The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
In an interview with Targeted Oncology™, Marcus Neubauer, MD, of The US Oncology Network, discusses the signs of physician ...
A prospective Canadian study suggests that moving beyond narrow, cancer-specific molecular panels toward broader genomic ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results